Medtronic said on November 16, 2026 that it plans to acquire Contego Medical, a privately held company in Raleigh, North Carolina that makes devices for treating carotid artery disease and for removing clots from peripheral blood vessels. Medtronic valued the deal at $380 million and said further payments could follow after the acquisition. It did not say whether it would pay in cash or stock.
The purchase covers Contego's Neuroguard IEP System, the recently approved Neuroguard IEP Direct System and the Excipio thrombectomy devices. Medtronic expects to complete the deal in the third quarter of its fiscal year, subject to customary closing conditions, and said it would be slightly dilutive to its adjusted earnings per share in fiscal 2027 and 2028 and neutral to positive after that.
The two companies already work together. In January 2025 Medtronic became Contego's exclusive distributor in the United States, and MedTech Dive reported that Medtronic has been a minority investor in the company since 2020.
What Contego Medical built
Contego was started by two physicians, Ravish Sachar, who is its chief executive, and Jay Yadav. Its products are built around what it calls integrated embolic protection: a filter attached to the same device used to treat a blocked artery, designed to catch debris that breaks loose during the procedure before it can travel to the brain.
That matters because carotid disease, in which the main arteries feeding the brain become narrowed or blocked, is behind about 20% of ischemic strokes, according to Medtronic. Opening those arteries is meant to lower stroke risk, but debris released during the procedure can itself cause a stroke.
The newest product, the Neuroguard IEP Direct System, is used in transcarotid artery revascularization, known as TCAR. Medtronic said it is the only such system that combines integrated embolic protection with flow reversal. In the PERFORMANCE III study, a prospective trial run at several centers, patients treated with the system had no strokes, no neurological deaths, no cranial nerve injuries and no heart attacks within 30 days, according to Medtronic.
Contego's Excipio devices are used for thrombectomy, the removal of blood clots, in patients with peripheral vascular disease. Medtronic said they would complement its own Liberant thrombectomy system.
“We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease.”
Why Medtronic is buying
Medtronic described the deal as part of a strategy of making targeted investments in its core businesses. David Moeller, who runs Medtronic Peripheral Vascular Health within its cardiovascular portfolio, said the company aimed to combine its clinical experience in peripheral and neurovascular care with Contego's products to become the clear leader in carotid revascularization.
The products also connect to Medtronic's neurovascular unit, which focuses on stroke. Linnea Burman, who leads Medtronic Neurovascular, said disability caused by stroke showed the need for new treatment options and that the acquisition would help doctors reach more patients with carotid artery disease.
Sachar said Contego had set out to build devices that improve results while making procedures simpler, and he thanked the physicians, study sites, employees and investors who had helped bring the products to patients.
The founders and the funding
Contego was founded in 2005, according to the Preqin database, and has been based in Raleigh since at least 2015. That year it closed a $5.6 million Series B round led by Hatteras Venture Partners, with Mountain Group Partners, Lookout Capital and Medical Mutual also investing. Doug Reed, a general partner at Hatteras, joined the board. At the time the company said it would use the money to expand its leadership, sales and engineering teams and to develop new products, and its Paladin carotid post-dilation balloon carried a CE mark in Europe.
Medtronic's announcement named Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health as backers. The total amount Contego raised was not reported in the sources reviewed, and neither company disclosed its headcount or revenue.
From distributor to owner
MedTech Dive reported in January 2025 that the distribution agreement included an option for Medtronic to buy Contego. The announcement on November 16 turns that relationship into full ownership, with Contego's carotid and thrombectomy products moving into Medtronic's portfolio once the deal closes.
Medtronic did not say what the possible post-acquisition payments depend on or how large they could be.




